STATE-OF-THE-ART PAPER
Role of Inflammation in Initiation and Perpetuation of Atrial FibrillationA Systematic Review of the Published Data
Tim T. Issac, MD,
Hisham Dokainish, MD, FACC and
Nasser M. Lakkis, MD, FACC*
Division of Cardiology, Baylor College of Medicine, Houston, Texas.
Manuscript received April 30, 2007;
revised manuscript received June 13, 2007,
accepted June 19, 2007.
* Reprint requests and correspondence: Dr. Nasser M. Lakkis, Professor of Medicine, 1709 Dryden, MS 9.90, Houston, Texas 77030. (Email: nlakkis{at}bcm.tmc.edu).
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Recent studies have indicated that inflammation might play a significant role in the initiation, maintenance, and perpetuation of AF. Inflammatory markers such as interleukin-6 and C-reactive protein are elevated in AF and correlate to longer duration of AF, success of cardioversion, and thrombogenesis. Furthermore, the inflammatory process might be modulated by the use of statins, angiotensin-converting enzyme inhibitors, or glucocorticoids. The purpose of this study is to analyze the current published reports on the relationship between inflammation and AF and the potential therapeutic options available to modulate the inflammatory milieu in AF.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | AERP = atrial effective refractory period | | AF = atrial fibrillation | | ARB = angiotensin receptor blocker | | CABG = cardiac bypass surgery | | CRP = C-reactive protein | | DCCV = direct current cardioversion | | IFN = interferon | | IL = interleukin | | PAF = paroxysmal atrial fibrillatioin | | RAS = renin-angiotensin system | | SEC = spontaneous echo contrast | | TGF = transforming growth factor | | TNF = tumor necrosis factor |
|
This article has been cited by other articles:
|
|
|
|
 
P. Kirchhof, G. Y. H. Lip, I. C. Van Gelder, J. Bax, E. Hylek, S. Kaab, U. Schotten, K. Wegscheider, G. Boriani, A. Brandes, et al.
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
Europace,
January 1, 2012;
14(1):
8 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Schnabel, K. F. Kerr, S. A. Lubitz, E. L. Alkylbekova, G. M. Marcus, M. F. Sinner, J. W. Magnani, P. A. Wolf, R. Deo, D. M. Lloyd-Jones, et al.
Large-Scale Candidate Gene Analysis in Whites and African Americans Identifies IL6R Polymorphism in Relation to Atrial Fibrillation: The National Heart, Lung, and Blood Institute's Candidate Gene Association Resource (CARe) Project
Circ Cardiovasc Genet,
October 1, 2011;
4(5):
557 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ahlehoff, G. H. Gislason, C. H. Jorgensen, J. Lindhardsen, M. Charlot, J. B. Olesen, S. Z. Abildstrom, L. Skov, C. Torp-Pedersen, and P. R. Hansen
Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study
Eur. Heart J.,
August 25, 2011;
(2011)
ehr285v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. M. Estes III, R. L. Sacco, S. M. Al-Khatib, P. T. Ellinor, J. Bezanson, A. Alonso, C. Antzelevitch, R. G. Brockman, P.-S. Chen, S. S. Chugh, et al.
American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association
Circulation,
July 19, 2011;
124(3):
363 - 372.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. X. Wong, H. S. Abed, P. Molaee, A. J. Nelson, A. G. Brooks, G. Sharma, D. P. Leong, D. H. Lau, M. E. Middeldorp, K. C. Roberts-Thomson, et al.
Pericardial Fat Is Associated With Atrial Fibrillation Severity and Ablation Outcome
J. Am. Coll. Cardiol.,
April 26, 2011;
57(17):
1745 - 1751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rahimi, J. Emberson, P. McGale, W. Majoni, A. Merhi, F. W. Asselbergs, V. Krane, P. W. Macfarlane, and PWM is acting on behalf of the PROSPER Executive
Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials
BMJ,
March 16, 2011;
342(mar16_2):
d1250 - d1250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Koyama, H. Tada, Y. Sekiguchi, T. Arimoto, H. Yamasaki, K. Kuroki, T. Machino, K. Tajiri, X. D. Zhu, M. Kanemoto-Igarashi, et al.
Prevention of Atrial Fibrillation Recurrence With Corticosteroids After Radiofrequency Catheter Ablation: A Randomized Controlled Trial
J. Am. Coll. Cardiol.,
October 26, 2010;
56(18):
1463 - 1472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Belhassen
Corticosteroid Therapy After Catheter Ablation of Atrial Fibrillation for an Authentic "Blanking Period"
J. Am. Coll. Cardiol.,
October 26, 2010;
56(18):
1473 - 1475.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Empana, X. Jouven, F. Canoui-Poitrine, G. Luc, M. Tafflet, B. Haas, D. Arveiler, J. Ferrieres, J.-B. Ruidavets, M. Montaye, et al.
C-Reactive Protein, Interleukin 6, Fibrinogen and Risk of Sudden Death in European Middle-Aged Men: The PRIME Study
Arterioscler Thromb Vasc Biol,
October 1, 2010;
30(10):
2047 - 2052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Sanoski
Prevalence, pathogenesis, and impact of atrial fibrillation
Am. J. Health Syst. Pharm.,
May 1, 2010;
67(9_Supplement_5):
S11 - S16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ramaraj
Independent predictors of postoperative atrial fibrillation
Eur J Cardiothorac Surg,
February 1, 2010;
37(2):
498 - 499.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Frasure-Smith, F. Lesperance, M. Habra, M. Talajic, P. Khairy, P. Dorian, D. Roy, and for the Atrial Fibrillation and Congestive Heart F
Elevated Depression Symptoms Predict Long-Term Cardiovascular Mortality in Patients With Atrial Fibrillation and Heart Failure
Circulation,
July 14, 2009;
120(2):
134 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Crandall, D. J. Bradley, D. L. Packer, and S. J. Asirvatham
Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Mayo Clin. Proc.,
July 1, 2009;
84(7):
643 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ashikaga and J. E Marine
Prevention of atrial fibrillation: another good reason to recommend statins to women?
Heart,
May 1, 2009;
95(9):
693 - 694.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C N Pellegrini, E Vittinghoff, F Lin, S B Hulley, and G M Marcus
Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial
Heart,
May 1, 2009;
95(9):
704 - 708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Lellouche, F. Sacher, M. Wright, I. Nault, J. Brottier, S. Knecht, S. Matsuo, O. Lomas, M. Hocini, M. Haissaguerre, et al.
Usefulness of C-reactive protein in predicting early and late recurrences after atrial fibrillation ablation
Europace,
May 1, 2009;
11(5):
662 - 664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Benjamin, P.-S. Chen, D. E. Bild, A. M. Mascette, C. M. Albert, A. Alonso, H. Calkins, S. J. Connolly, A. B. Curtis, D. Darbar, et al.
Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop
Circulation,
February 3, 2009;
119(4):
606 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. Letsas, R. Weber, G. Burkle, C. C. Mihas, J. Minners, D. Kalusche, and T. Arentz
Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation
Europace,
February 1, 2009;
11(2):
158 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Smit and I. C. Van Gelder
Is inflammation a risk factor for recurrent atrial fibrillation?
Europace,
February 1, 2009;
11(2):
138 - 139.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Schoonderwoerd, M. D. Smit, L. Pen, and I. C. Van Gelder
New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'
Europace,
June 1, 2008;
10(6):
668 - 673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nattel, B. Burstein, and D. Dobrev
Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Circ Arrhythm Electrophysiol,
April 1, 2008;
1(1):
62 - 73.
[Full Text]
[PDF]
|
|
|
|
